Solid Tumor – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 1 PAGES: 532

More Info
									Solid Tumor – Pipeline Review, H1 2012




                         Solid Tumor – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1622IDB
                                                                                            Publication Date: January 2012




Solid Tumor – Pipeline Review, H1 2012                                                     GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Solid Tumor – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ............................................................................................................................................................................... 11
    List of Figures .............................................................................................................................................................................. 21
Introduction....................................................................................................................................................................................... 22
    Global Markets Direct Report Coverage ...................................................................................................................................... 22
Solid Tumor Overview ...................................................................................................................................................................... 23
Therapeutics Development............................................................................................................................................................... 24
    An Overview of Pipeline Products for Solid Tumor ...................................................................................................................... 24
Solid Tumor Therapeutics under Development by Companies ........................................................................................................ 26
Solid Tumor Therapeutics under Investigation by Universities/Institutes.......................................................................................... 47
Late Stage Products ......................................................................................................................................................................... 60
    Comparative Analysis .................................................................................................................................................................. 60
Mid Clinical Stage Products.............................................................................................................................................................. 61
    Comparative Analysis .................................................................................................................................................................. 61
Early Clinical Stage Products ........................................................................................................................................................... 62
    Comparative Analysis .................................................................................................................................................................. 62
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 63
    Comparative Analysis .................................................................................................................................................................. 63
Solid Tumor Therapeutics – Products under Development by Companies ...................................................................................... 64
Solid Tumor Therapeutics – Products under Investigation by Universities/Institutes...................................................................... 117
Companies Involved in Solid Tumor Therapeutics Development ................................................................................................... 166
    Bristol-Myers Squibb Company ................................................................................................................................................. 166
    Genzyme Corporation ............................................................................................................................................................... 167
    Johnson & Johnson ................................................................................................................................................................... 168
    Boehringer Ingelheim GmbH ..................................................................................................................................................... 169
    F. Hoffmann-La Roche Ltd. ....................................................................................................................................................... 170
    Kyowa Hakko Kirin Co., Ltd. ...................................................................................................................................................... 171
    Abbott Laboratories ................................................................................................................................................................... 172
    Biogen Idec Inc. ......................................................................................................................................................................... 173
    Shionogi & Co., Ltd.................................................................................................................................................................... 174
    Amgen Inc. ................................................................................................................................................................................ 175
    Sanofi-Aventis ........................................................................................................................................................................... 176
    Adherex Technologies Inc. ........................................................................................................................................................ 177
    AstraZeneca PLC ...................................................................................................................................................................... 178
    Eli Lilly and Company ................................................................................................................................................................ 179
    GlaxoSmithKline plc .................................................................................................................................................................. 180
    Seattle Genetics, Inc. ................................................................................................................................................................ 181
    Tekmira Pharmaceuticals Corp. ................................................................................................................................................ 182
    Genentech, Inc. ......................................................................................................................................................................... 183
    Nektar Therapeutics .................................................................................................................................................................. 185
    MedImmune LLC ....................................................................................................................................................................... 186
    Gilead Sciences, Inc. ................................................................................................................................................................. 187



Solid Tumor – Pipeline Review, H1 2012                                                                                                       GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Solid Tumor – Pipeline Review, H1 2012



    Biotest AG ................................................................................................................................................................................. 188
    Daiichi Sankyo Company, Ltd.................................................................................................................................................... 189
    Merck & Co., Inc. ....................................................................................................................................................................... 190
    Dainippon Sumitomo Pharma Co., Ltd. ..................................................................................................................................... 192
    Cangene Corporation ................................................................................................................................................................ 193
    Oxford BioMedica plc ................................................................................................................................................................ 194
    Micromet, Inc. ............................................................................................................................................................................ 195
    Scil Proteins GmbH ................................................................................................................................................................... 196
    Infinity Pharmaceuticals, Inc. ..................................................................................................................................................... 197
    Takeda Pharmaceutical Company Limited ................................................................................................................................ 198
    YM BioSciences Inc................................................................................................................................................................... 199
    Light Sciences Oncology, Inc. ................................................................................................................................................... 200
    Ipsen S.A. .................................................................................................................................................................................. 201
    Nanotherapeutics, Inc................................................................................................................................................................ 202
    Prolexys Pharmaceuticals, Inc................................................................................................................................................... 203
    Bio-Path Holdings, Inc. .............................................................................................................................................................. 204
    Ambrilia Biopharma Inc. ............................................................................................................................................................ 205
    Aposense Ltd............................................................................................................................................................................. 206
    ZIOPHARM Oncology, Inc. ........................................................................................................................................................ 207
    Millennium Pharmaceuticals, Inc. .............................................................................................................................................. 208
    Novartis AG ............................................................................................................................................................................... 209
    ImClone Systems Incorporated ................................................................................................................................................. 211
    Astellas Pharma Inc................................................................................................................................................................... 212
    BioMarin Pharmaceutical Inc. .................................................................................................................................................... 213
    Cephalon, Inc. ........................................................................................................................................................................... 214
    Chong Kun Dang Pharmaceutical ............................................................................................................................................. 215
    Chugai Pharmaceutical Co. Ltd ................................................................................................................................................. 216
    Daewoong Pharmaceutical Co., Ltd. ......................................................................................................................................... 217
    Eisai Co., Ltd. ............................................................................................................................................................................ 218
    Genta Incorporated.................................................................................................................................................................... 219
    GTC Biotherapeutics, Inc. ......................................................................................................................................................... 220
    ImmunoGen, Inc. ....................................................................................................................................................................... 221
    Kowa Company, Ltd. ................................................................................................................................................................. 222
    Nippon Kayaku Co., Ltd............................................................................................................................................................. 223
    Ono Pharmaceutical Co., Ltd..................................................................................................................................................... 224
    OSI Pharmaceuticals, Inc. ......................................................................................................................................................... 225
    Pfizer Inc.................................................................................................................................................................................... 226
    Sunesis Pharmaceuticals, Inc.................................................................................................................................................... 228
    SuperGen, Inc. .......................................................................................................................................................................... 229
    Taiho Pharmaceutical Co., Ltd. ................................................................................................................................................. 230
    Takara Holdings Inc................................................................................................................................................................... 231
    Teva Pharmaceutical Industries Limited .................................................................................................................................... 232
    Cell Therapeutics, Inc. ............................................................................................................................................................... 233
    Genmab A/S .............................................................................................................................................................................. 234


Solid Tumor – Pipeline Review, H1 2012                                                                                                       GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Solid Tumor – Pipeline Review, H1 2012



    Progenics Pharmaceuticals, Inc. ............................................................................................................................................... 235
    Enzon Pharmaceuticals, Inc. ..................................................................................................................................................... 236
    Santaris Pharma A/S ................................................................................................................................................................. 237
    Silence Therapeutics plc. .......................................................................................................................................................... 238
    Calando Pharmaceuticals, Inc. .................................................................................................................................................. 239
    Exelixis, Inc................................................................................................................................................................................ 240
    Aduro BioTech ........................................................................................................................................................................... 241
    Cyclacel Pharmaceuticals Inc. ................................................................................................................................................... 242
    Celgene Corporation ................................................................................................................................................................. 243
    Onyx Pharmaceuticals, Inc. ....................................................................................................................................................... 244
    Bayer AG ................................................................................................................................................................................... 245
    Incyte Corporation ..................................................................................................................................................................... 246
    Geron Corporation ..................................................................................................................................................................... 247
    MannKind Corporation............................................................................................................................................................... 248
    Merck KGaA .............................................................................................................................................................................. 249
    Access Pharmaceuticals, Inc. .................................................................................................................................................... 250
    4SC AG ..................................................................................................................................................................................... 251
    EntreMed, Inc. ........................................................................................................................................................................... 252
    EpiCept Corporation .................................................................................................................................................................. 253
    Genesis Research and Development Corporation Ltd. ............................................................................................................. 254
    Hana Biosciences, Inc. .............................................................................................................................................................. 255
    Celldex Therapeutics, Inc. ......................................................................................................................................................... 256
    AEterna Zentaris Inc. ................................................................................................................................................................. 257
    ImmunoCellular Therapeutics, Ltd. ............................................................................................................................................ 258
    Ariad Pharmaceuticals, Inc. ....................................................................................................................................................... 259
    Lorus Therapeutics Inc .............................................................................................................................................................. 260
    Marshall Edwards, Inc. .............................................................................................................................................................. 261
    MediciNova, Inc. ........................................................................................................................................................................ 262
    Basilea Pharmaceutica Ltd. ....................................................................................................................................................... 263
    MethylGene Inc ......................................................................................................................................................................... 264
    Bionomics Limited ..................................................................................................................................................................... 265
    MultiCell Technologies, Inc. ....................................................................................................................................................... 266
    Circadian Technologies Limited................................................................................................................................................. 267
    Oncolytics Biotech Inc. .............................................................................................................................................................. 268
    Oncothyreon Inc ........................................................................................................................................................................ 269
    OncoVista Innovative Therapies, Inc. ........................................................................................................................................ 270
    OXiGENE, Inc............................................................................................................................................................................ 271
    Patrys Limited ............................................................................................................................................................................ 272
    Peregrine Pharmaceuticals, Inc. ................................................................................................................................................ 273
    Curis, Inc. .................................................................................................................................................................................. 274
    Anadys Pharmaceuticals, Inc .................................................................................................................................................... 275
    ARQULE, INC............................................................................................................................................................................ 276
    ADVENTRX Pharmaceuticals.................................................................................................................................................... 277
    Alexion Pharmaceuticals, Inc..................................................................................................................................................... 278


Solid Tumor – Pipeline Review, H1 2012                                                                                                       GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(4)
Solid Tumor – Pipeline Review, H1 2012



    Cytokinetics, Inc ........................................................................................................................................................................ 279
    TopoTarget A/S ......................................................................................................................................................................... 280
    Mundipharma International Limited ........................................................................................................................................... 281
    CytRx Corporation ..................................................................................................................................................................... 282
    Regeneron Pharmaceuticals, Inc............................................................................................................................................... 283
    Oncogenex Pharmaceuticals, Inc. ............................................................................................................................................. 284
    Pharmacyclics, Inc..................................................................................................................................................................... 285
    Dendreon Corporation ............................................................................................................................................................... 286
    Array BioPharma Inc. ................................................................................................................................................................ 287
    Thallion Pharmaceuticals Inc. .................................................................................................................................................... 288
    Transgene SA............................................................................................................................................................................ 289
    Progen Pharmaceuticals Limited ............................................................................................................................................... 290
    TapImmune Inc.......................................................................................................................................................................... 291
    Jiangsu Hengrui Medicine Co., Ltd. ........................................................................................................................................... 292
    Threshold Pharmaceuticals, Inc. ............................................................................................................................................... 293
    Galapagos NV ........................................................................................................................................................................... 294
    Synta Pharmaceuticals Corp. .................................................................................................................................................... 295
    CrystalGenomics, Inc. ............................................................................................................................................................... 296
    Natco Pharma Limited ............................................................................................................................................................... 297
    Oasmia Pharmaceutical AB ....................................................................................................................................................... 298
    Algeta ASA ................................................................................................................................................................................ 299
    Protox Therapeutics Inc............................................................................................................................................................. 300
    e-Therapeutics plc ..................................................................................................................................................................... 301
    Rexahn Pharmaceuticals, Inc. ................................................................................................................................................... 302
    SymBio Pharmaceuticals Limited .............................................................................................................................................. 303
    Eisai Inc. .................................................................................................................................................................................... 304
    Morphotek, Inc. .......................................................................................................................................................................... 305
    Spectrum Pharmaceuticals, Inc. ................................................................................................................................................ 306
    Debiopharm Group .................................................................................................................................................................... 307
    Chroma Therapeutics Ltd. ......................................................................................................................................................... 308
    Colby Pharmaceutical Company ............................................................................................................................................... 309
    Affimed Therapeutics AG .......................................................................................................................................................... 310
    Wilex AG ................................................................................................................................................................................... 311
    INSYS Therapeutics, Inc. .......................................................................................................................................................... 312
    Ambit Biosciences Corporation.................................................................................................................................................. 313
    Philogen S.p.A. .......................................................................................................................................................................... 314
    Acceleron Pharma, Inc. ............................................................................................................................................................. 315
    Pieris AG ................................................................................................................................................................................... 316
    Glycotope GmbH ....................................................................................................................................................................... 317
    Neovacs SA ............................................................................................................................................................................... 318
    ERYtech Pharma ....................................................................................................................................................................... 319
    Curacyte AG .............................................................................................................................................................................. 320
    Apogenix GmbH ........................................................................................................................................................................ 321
    BioNumerik Pharmaceuticals, Inc. ............................................................................................................................................. 322


Solid Tumor – Pipeline Review, H1 2012                                                                                                       GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(5)
Solid Tumor – Pipeline Review, H1 2012



    Altor BioScience Corporation..................................................................................................................................................... 323
    Provecs Medical GmbH ............................................................................................................................................................. 324
    EnGeneIC Ltd ............................................................................................................................................................................ 325
    Angiogene Pharmaceuticals Ltd. ............................................................................................................................................... 326
    GenSpera, Inc. .......................................................................................................................................................................... 327
    Phoenix Biotechnology, Inc. ...................................................................................................................................................... 328
    Allozyne, Inc. ............................................................................................................................................................................. 329
    Coronado Biosciences, Inc. ....................................................................................................................................................... 330
    Cerulean Pharma, Inc................................................................................................................................................................ 331
    MacroGenics, Inc....................................................................................................................................................................... 332
    Pervasis Therapeutics, Inc. ....................................................................................................................................................... 333
    Pharmascience Inc. ................................................................................................................................................................... 334
    Arno Therapeutics, Inc. ............................................................................................................................................................. 335
    ACT Biotech, Inc........................................................................................................................................................................ 336
    OncoMed Pharmaceuticals, Inc. ................................................................................................................................................ 337
    TetraLogic Pharmaceuticals ...................................................................................................................................................... 338
    Boston Biomedical, Inc. ............................................................................................................................................................. 339
    Five Prime Therapeutics, Inc. .................................................................................................................................................... 340
    PanaGin Pharmaceuticals Inc. .................................................................................................................................................. 341
    Vaccinex, Inc. ............................................................................................................................................................................ 342
    Azaya Therapeutics, Inc. ........................................................................................................................................................... 343
    Semafore Pharmaceuticals, Inc. ................................................................................................................................................ 344
    CanBas Co., Ltd. ....................................................................................................................................................................... 345
    S*BIO Pte Ltd ............................................................................................................................................................................ 346
    Merrimack Pharmaceuticals, Inc................................................................................................................................................ 347
    PTC Therapeutics, Inc. .............................................................................................................................................................. 348
    RESprotect GmbH ..................................................................................................................................................................... 349
    Conatus Pharmaceuticals Inc. ................................................................................................................................................... 350
    Deciphera Pharmaceuticals, LLC .............................................................................................................................................. 351
    ProNAi Therapeutics, Inc........................................................................................................................................................... 352
    Mersana Therapeutics, Inc. ....................................................................................................................................................... 353
    Vascular Biogenics Ltd. ............................................................................................................................................................. 354
    Jennerex Biotherapeutics, Inc. .................................................................................................................................................. 355
    Stemline Therapeutics, Inc. ....................................................................................................................................................... 356
    Axelar AB................................................................................................................................................................................... 357
    Endocyte, Inc. ............................................................................................................................................................................ 358
    Proacta, Inc. .............................................................................................................................................................................. 359
    Cornerstone Pharmaceuticals, Inc............................................................................................................................................. 360
    Omnitura Therapeutics Inc. ....................................................................................................................................................... 361
    Advenchen Laboratories, LLC ................................................................................................................................................... 362
    AndroScience Corporation ........................................................................................................................................................ 363
    Onconova Therapeutics, Inc ...................................................................................................................................................... 364
    MolMed S.p.A. ........................................................................................................................................................................... 365
    Intellikine, Inc. ............................................................................................................................................................................ 366


Solid Tumor – Pipeline Review, H1 2012                                                                                                       GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(6)
Solid Tumor – Pipeline Review, H1 2012



    Syndax Pharmaceuticals, Inc. ................................................................................................................................................... 367
    Myriad Pharmaceuticals, Inc...................................................................................................................................................... 368
    NOXXON Pharma AG ............................................................................................................................................................... 369
    NovaLead Pharma Pvt. Ltd........................................................................................................................................................ 370
    Esperance Pharmaceuticals, Inc. .............................................................................................................................................. 371
    Mirna Therapeutics, Inc. ............................................................................................................................................................ 372
    Transtech Pharma, Inc. ............................................................................................................................................................. 373
    BiPar Sciences, Inc. .................................................................................................................................................................. 374
    Xencor, Inc. ............................................................................................................................................................................... 375
    ImmunoVaccine Technologies Inc. ............................................................................................................................................ 376
    Welichem Biotech Inc. ............................................................................................................................................................... 377
    Oncolys BioPharma Inc. ............................................................................................................................................................ 378
    APEIRON Biologics AG ............................................................................................................................................................. 379
    HENKAN Pharmaceutical Co., Ltd. ........................................................................................................................................... 380
    Immunocore Limited. ................................................................................................................................................................. 381
    BIND Biosciences, Inc. .............................................................................................................................................................. 382
    NewLink Genetics Corporation .................................................................................................................................................. 383
    Tragara Pharmaceuticals, Inc. ................................................................................................................................................... 384
    Taiwan Liposome Company ...................................................................................................................................................... 385
    Drais Pharmaceuticals, Inc. ....................................................................................................................................................... 386
    PharmaMar, S.A. ....................................................................................................................................................................... 387
    Kiadis Pharma B.V. ................................................................................................................................................................... 388
    Quintessence Biosciences, Inc. ................................................................................................................................................. 389
    Bellicum Pharmaceuticals, Inc. .................................................................................................................................................. 390
    VentiRx Pharmaceuticals, Inc. ................................................................................................................................................... 391
    KaloBios Pharmaceuticals, Inc. ................................................................................................................................................. 392
    AB Science ................................................................................................................................................................................ 393
    arGEN-X BV .............................................................................................................................................................................. 394
    Kinex Pharmaceuticals, LLC...................................................................................................................................................... 395
    Adamis Pharmaceuticals Corporation ....................................................................................................................................... 396
    SynDevRx™, Inc. ...................................................................................................................................................................... 397
    Tigris Pharmaceuticals, Inc........................................................................................................................................................ 398
    to-BBB technologies BV ............................................................................................................................................................ 399
    Cylene Pharmaceuticals, Inc. .................................................................................................................................................... 400
    Nereus Pharmaceuticals, Inc. ....
								
To top